AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03265665 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced usual care
Description: Participants will attend 1 two hour asthma education/physical activity session at community location near them. Participants will review basic asthma topics in a didactic session and will include exercising with asthma and exercise-induced asthma. Participants will be given Fitbit and provided instructions on how to use it. Participants may receive 2 newsletters with information on asthma and reminder texts regarding data collection visits.~Data will be collected at 3 time points: baseline, 24-weeks and 36-weeks.
Study NCT02457481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embryo Culture medium
Description: Two step sequential embryo culture medium system
Study NCT03758339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: Single dose of 300 mg of \[¹⁴C\]-tucatinib containing approximately 150 μCi of \[¹⁴C\] radioactivity
Study NCT02828930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Idasanutlin 300 mg tablet orally on Day 1; 400 mg tablet orally on Day 11 and Day 19. Participants, who are eligible to enter in optional treatment extension phase, will continue treatment with idasanutlin 200 mg tablet orally once daily for 5 days of 28-day cycle.
Study NCT02828930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to idasanutlin aqueous dispersion will be administered orally on Day 11.
Study NCT02828930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C]-radiolabeled Idasanutlin
Description: \[13C\]-radiolabeled idasanutlin 100 mcg will be administered as IV infusion over 15-minute on Day 1.
Study NCT02828930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-radiolabeled Idasanutlin
Description: \[14C\]-radiolabeled idasanutlin 100 mg capsule (2, 50 mg capsules containing approximately 100 microcurie of radioactivity) will be administered orally on Day 1.
Study NCT03956134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Test Product 1
Description: Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 1 contains different amounts of excipients than Tapentadol Test Product 2
Study NCT03956134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Test Product 2
Description: Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 2 contains different amounts of excipients than Tapentadol Test Product 1
Study NCT03956134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tapentadol Prolonged-release Reference Product
Description: Tapentadol PR tablet containing 116 mg of tapentadol hydrochloride
Study NCT03820180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product
Description: 2 inhalations of Test and Reference product in each study period
Study NCT04413565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral total knee arthroplasty
Description: Two surgeon bilateral TKA group
Study NCT04413565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sequenced bilateral TKA
Description: Single surgeon bilateral TKA group
Study NCT02627625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: 4 inhalations
Study NCT01520545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gablofen® 3 mg/mL (baclofen injection)
Description: This is a prospective twelve-month Phase IIIb clinical safety trial followed by a 2-year, Phase IV study that will be conducted at clinical trial sites that are experienced with the use of intrathecal baclofen. Patients will be followed for the duration of their treatment with Gablofen® (baclofen injection) 3 mg/mL using the SynchroMed® II Programmable Pump or until the study is terminated.
Study NCT02627625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: 4 inhalations
Study NCT01240356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-MHz transcranial Doppler ultrasound
Description: 2-hours of hands-free ultrasound will be insonated continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
Study NCT01240356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-MHz transcranial Doppler ultrasound insonation
Description: 2-hours of hands-free ultrasound delivered to in the intracranial vessels.
Study NCT01893320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vosaroxin
Description: Phase I Starting Dose: 90 mg/m2 by vein on Days 1 and 4 of each cycle.~Phase II Starting Dose: 70 mg/m2 by vein on Days 1 and 4 of each cycle, or maximum tolerated dose from Phase I.
Study NCT01893320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Phase I and II: 20 mg/m2 by vein daily for 5 consecutive days (Days 1 to 5).
Study NCT03820180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product
Description: 2 inhalations of Test and Reference product in each study period
Study NCT01520545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SynchroMed® II Programmable Pump
Description: Intrathecal programmable pump
Study NCT02565017 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus groups
Description: After the presentation of the of IBM Watson Oncology at the opening of the focus group, participants will be asked to fill out a de-identified brief 15-item questionnaire to assess participants' first impressions of IBM Watson Oncology. The questionnaire will be self administered, and will take approximately 5 minutes to complete. Completed questionnaires will be collected by a member of the study staff, and the focus group will proceed with introductions. The focus group will be audio recorded from the completion of the introductions and notes will be taken. The focus group guide will address the study aims. At the end of the focus group, participants will complete a 7-item questionnaire to capture simple demographic information including education, income, and health literacy. This questionnaire will take 3-5 minutes to complete.
Study NCT01874977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: Will receive the educational booklet and discussion, plus a pedometer and a diary to record their daily step counts from the pedometer.
Study NCT02961673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HU-014 Inj
Description: Clostridium botulinum type A
Study NCT02961673 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botox Inj
Description: Clostridium botulinum type A
Study NCT02754557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath-Focused Meditation
Description: Participants will attend two breath-focused meditation sessions per week for three weeks. During the breath focus task, participants are asked to alternatively focus their breathing (1.5 minutes of breathing and 15 seconds of rest). Participants will be asked to attend to the changing patterns of physical sensations as the breath moves in and out of your body. Focus your awareness on any sensations you may experience (e.g., your abdominal wall rising). Follow the sensations as you breathe in and all the way through until your breath leaves your body.
Study NCT02482363 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVA radiation
Description: 20 minutes of low dose UVA from a phototherapy unit
Study NCT02482363 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: 20 minutes of sham control exposure
Study NCT01566123 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant intensity-modulated radiation therapy (IMRT)
Description: neoadjuvant intensity-modulated radiation therapy, single dose 2.0-2.4 Gy, total dose 50-56 Gy
Study NCT01566123 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intraoperative radiation therapy (IORT)
Description: during surgery, 10-12 Gy (90% isodose) to the tumor bed or residual disease
Study NCT01270581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula
Description: Humidified high flow nasal cannula (HFNC) has emerged as an alternative respiratory modality for late preterm newborns with respiratory distress. Like NCPAP, oxygen is delivered to the infant via nasal prongs and provides a continuous distending pressure. Unlike the nasal prongs for NCPAP (which fit tightly in the nares), the nasal cannula for HFNC have smaller, loose-fitting prong. With HFNC, positive airway pressure is achieved by high gas flow through the cannula into the external nares which provide resistance to expiration and facilitate inspiration. The distending pressure is determined by the size and structure of the nasal cannula, gas flow rate, and the neonate's airway anatomy 4,5,7.
Study NCT01270581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bubble Nasal CPAP
Description: NCPAP provides continuous distending airway pressure during inspiration and expiration via nasal prongs; this has been shown to increase lung volume by increasing alveolar size, recruiting collapsed alveoli, and preventing atelectasis. Improved lung volumes decrease V/Q mismatch and improve the clinical course of neonates with RDS, and as such, early NCPAP use often avoids the need for intubation and mechanical ventilation. Newborns receiving bubble NCPAP will be placed on a PEEP 5cm H2O, and supplemental oxygen will be provided to maintain oxygen saturation between 88-93% (standard of care group) as is standard practice. The size of the nasal prongs used will be based on the subject's weight as per the manufacturer instructions.
Study NCT00506051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (vandetanib) 100mg
Description: once daily oral tablet
Study NCT00506051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: intravenous infusion
Study NCT00506051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (vandetanib) 300mg
Study NCT03792776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cuff inflation with air
Description: Endotracheal tube cuff inflation with air
Study NCT03792776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cuff inflation with lidocaine 1%
Description: Endotracheal tube cuff inflation with lidocaine 1%
Study NCT03792776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cuff inflation with lidocaine 2%
Description: Endotracheal tube cuff inflation with lidocaine 2%
Study NCT03792776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Induction of anesthesia
Description: The induction of anesthesia will be made following a preoxygenation with a facial mask with 100% Oxygen. It consists on the intravenous injection of Sufentanil 5 mcg or Fentanyl 50mcg, Lidocaine 1mg/Kg, Propofol 2.5mg/kg, Rocuronium 0.6mg/kg or Cisatracurium 0.15mg/kg.
Study NCT03792776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction of anesthesia
Description: The induction of anesthesia will be made following a preoxygenation with a facial mask with 100% Oxygen. It consists on the intravenous injection of Sufentanil 5 mcg or Fentanyl 50mcg, Lidocaine 1mg/Kg, Propofol 2.5mg/kg, Rocuronium 0.6mg/kg or Cisatracurium 0.15mg/kg.
Study NCT05399212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPT-20
Description: FPT-20 should be used regularly, the daily maintenance dose is 1 tablet once a day(>6 to 12 months) until the therapeutic purpose is achieved.
Study NCT02754557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physiological Feedback
Description: Participants will receive breath feedback, via dynamic velocity estimates from a respiration belt, which allows an analog of breath to be felt as vibration on their wrist via a tactile transducer on a table. The transducer is tuned to produce low frequencies so there is more vibration and less of an audible component than a regular speaker would produce.
Study NCT03792776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of anesthesia
Description: Maintenance of anesthesia will be done by sevoflurane + nitrous oxide, and reinjections of morphinomimetics and curare will be made as needed (the total doses will be noted at the end of the intervention).
Study NCT03274466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Incision Negative Pressure Therapy (ciNPT)
Description: Closed Incision Negative Pressure Therapy applied through a foam bolster with a wicking interface fabric that includes 0.019% ionic silver at 125 mmHg of negative pressure for 5-7 days.
Study NCT03274466 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Dressing
Description: A standard silver-impregnated dressing applied to a closed surgical incision for 5-7 days post-operatively.
Study NCT06691646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gaze-control training game
Description: An eyetracker-controlled computer game designed to improve attentional control by training inhibitory control over direction of gaze. It includes six mini-games, each designed to train different aspects of oculomotor control, including selective attention, motor inhibition, motor timing, and spatial working memory.
Study NCT02531451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Study NCT02531451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Study NCT03057340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dribble vaccine
Description: DRibble vaccine with DC/CIK(The experimental group) DRibble vaccine will be administered at day1,22,55
Study NCT03499743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyoscine butyl bromide
Description: intake of 10 mg hyoscine butyl bromide (buscopan) orally in addition to a placebo similar to Celecoxib 2 hours before IUD insertion
Study NCT03499743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg
Description: Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide
Study NCT03499743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: a placebo similar to hyoscine butyl bromide in addition to a placebo similar to Celecoxib.
Study NCT04003402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8062
Description: oral
Study NCT03792776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maintenance of anesthesia
Description: Maintenance of anesthesia will be done by sevoflurane + nitrous oxide, and reinjections of morphinomimetics and curare will be made as needed (the total doses will be noted at the end of the intervention).
Study NCT04003402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: oral
Study NCT04003402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8062 Placebo
Description: oral
Study NCT04003402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol Placebo
Description: oral
Study NCT03652883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ItFits-toolkit
Description: The ItFits-toolkit provides evidence-informed methods, materials, knowledge on determinants and implementation strategies, and concrete guidance on tailoring implementation strategies to local determinants of practices, apply them and evaluate their impact. It applies a standardised four-step approach to iteratively develop evidence-informed implementation strategies. The ItFits-toolkit is based on the Normalisation Process Theory (NPT), which suggests that lasting changes in practice only happen through people working together. The ItFits toolkit functions as an online self-help toolkit with minimal support. The toolkit will provide instructions for the IL to establish a core team and to create a sounding board consisting to enable co-creation.
Study NCT03652883 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implementation as Usual
Description: IAU refers to any existing efforts to embed and integrate iCBT within an organisation.
Study NCT02685046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.
Study NCT03225729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRYOBEAUTY MAINS ET DECOLLETE
Description: The intervention lasts up to 6.5 s. The device will be applied on spots \<6 mm which are previously selected by the investigator team.
Study NCT03599713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: INCMGA00012 administered at 500 milligrams (mg) by intravenous infusion once every 4 weeks
Study NCT03792776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: The intubation is made by a N° 7.5 tube in men and a N° 7 tube in women. Cuff inflation will be done upon placement of the endotracheal tube. The cuff's pressure will be monitored at several intervals of the intervention and kept \< or = 20 centimeter of water (cmH2O).
Study NCT03792776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Description: The intubation is made by a N° 7.5 tube in men and a N° 7 tube in women. Cuff inflation will be done upon placement of the endotracheal tube. The cuff's pressure will be monitored at several intervals of the intervention and kept \< or = 20 centimeter of water (cmH2O).
Study NCT03792776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systematic post-operative analgesia
Description: All patients will receive Paracetamol every 6 hours for the first 24 hours after the end of surgery.
Study NCT03225729 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Liquid nitrogen
Description: The intervention lasts up to 3 s. The liquid is stored in well-isolated recipients. Each patient has his recipient to avoid contamination. The investigator applies on spots \<6 mm a small amount of nitrogen liquid.
Study NCT03792776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic post-operative analgesia
Description: All patients will receive Paracetamol every 6 hours for the first 24 hours after the end of surgery.
Study NCT04081844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306
Description: Ezetimibe 10mg / Rosuvastatin 20mg (Rosuzet)
Study NCT04081844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0904
Description: Amlodipine 5mg(Norvasc)
Study NCT04081844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0608
Description: Losartan 100mg(Cozaar)
Study NCT00174616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, capecitabine, radiotherapy
Description: * Oxaliplatin 50mg/m² I.V. 2 hours weekly x 5 doses~* Capecitabine 825mg/m² P.O. B.I.D. daily x 5 days x 5 weeks~* Radiotherapy 45 Gy total (1.8Gy/dose) 25 fractions daily x 5 days x 5 weeks
Study NCT04239703 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MMDx
Description: Portion of kidney transplant indication biopsy
Study NCT04239703 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prospera
Description: Transplant patient blood sample
Study NCT04239703 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HLA antibody
Description: Transplant patient blood sample
Study NCT03610438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin (IO)
Description: After course 1 MRD will be evaluated:~- patients MRD negative will enter into short maintenance or long maintenance according to investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance.
Study NCT02805348 — intervention group
Intervention type: DRUG
Intervention: Bixalomer
Description: Oral
Study NCT03610438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin (IO)
Description: After course 2 MRD will be evaluated; patients MRD negative will enter into short maintenance or long maintenance by investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance.
Study NCT04604314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEREC Tessera
Description: Full ceramic endocrown restorations will be made from the high strength ceramic, CEREC Tessera
Study NCT01800396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk protein
Study NCT01800396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk protein rich in phospholipids
Study NCT04102943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus tablet
Description: * Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment.
Study NCT04102943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus capsules
Description: * Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment.
Study NCT03584100 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet 8000
Description: Pneumatic tourniquet with appropriate upper extremity cuff, pressure sensing, and ability to set device at 40 mmHg of pressure